Shares of Harmony Biosciences surged 11.2% to $39.58 after the rare-disease drugmaker delivered a record second quarter that blew past Wall Street expectations on both the top and bottom lines. The company reported earnings of $1.28 per share, beating estimates of $1.02 by $0.26, on revenue of $261.3 million that topped the $253.4 million consensus by nearly $8 million. The results force a pointed question: is Harmony finally being priced for its growth, or is the rally still undervaluing a company on the cusp of $1 billion in annual sales?
More Patients, Bigger Sales Force, Record Quarter
Revenue represented a 30% year-over-year jump, which management attributed to a 20% expansion of the field sales team and new reimbursement processes that sped up patient access.
The 450-patient increase in Q2 was the highest second-quarter growth in the drug's history.
The U.S. narcolepsy market has roughly 80,000 diagnosed patients , and with approximately 8,950 now on the drug, penetration is still only ~11% — leaving significant room to grow without any new indications.
Earnings Nearly Doubled, But Costs Are Shifting
Diluted EPS rose to $1.28 from $0.68 a year earlier, and net income reached $75.4 million, as revenue growth outweighed pressure from new royalty obligations that pushed cost of product sold to 24.2% of revenue.
Cash and investments stood at $962 million against just $155 million in debt — a war chest that funds pipeline expansion without diluting shareholders.
The Patent Clock and the Pipeline Race The biggest long-term risk is competition. Harmony settled its main patent fight with Lupin, delaying generic entry until January 2030 at the earliest.
Litigation with one remaining generic challenger continues. To build beyond the flagship narcolepsy drug, Harmony is advancing an experimental next-generation sleep treatment into Phase 2 studies in mid-2027 and has an improved formulation of its current drug awaiting an FDA decision by April 1, 2027.
Valuation Still Looks Modest — If Growth Holds At $39.58, Harmony's market cap sits near $2.3 billion — roughly 2.2 times its guided $1.02 billion midpoint revenue. The median analyst target before the earnings beat was just $36 , meaning the stock has already leapt above consensus. The quarter proves the commercial engine works. The unresolved question is whether Harmony can diversify fast enough before generics arrive — or whether investors are paying full price for a single drug's best years.